Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations.
暂无分享,去创建一个
M. Arendrup | K. Nielsen | D. Perlin | D. Sanglard | R. Jørgensen | R. H. Jensen | L. V. Silva | K. Astvad | E. G. Mathiasen | Ghazalel Doroudian
[1] M. Arendrup,et al. Echinocandin resistance: an emerging clinical problem? , 2014, Current opinion in infectious diseases.
[2] M. Schuler,et al. Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans , 2014, Antimicrobial Agents and Chemotherapy.
[3] M. Cuenca‐Estrella. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[4] M. Cuenca‐Estrella,et al. EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole , 2014, Mycoses.
[5] M. Arendrup,et al. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. , 2013, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[6] Andrea Lohberger,et al. Distinct Roles of Candida albicans Drug Resistance Transcription Factors TAC1, MRR1, and UPC2 in Virulence , 2013, Eukaryotic Cell.
[7] P. Le Pape,et al. Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans. , 2013, International journal of antimicrobial agents.
[8] A. Fusco-Almeida,et al. Antifungal Efficacy during Candida krusei Infection in Non-Conventional Models Correlates with the Yeast In Vitro Susceptibility Profile , 2013, PloS one.
[9] D. Kelly,et al. Two Clinical Isolates of Candida glabrata Exhibiting Reduced Sensitivity to Amphotericin B Both Harbor Mutations in ERG2 , 2012, Antimicrobial Agents and Chemotherapy.
[10] M. Arendrup,et al. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[11] D. Kontoyiannis,et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. , 2011, The Journal of infectious diseases.
[12] P. Shukla,et al. Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans. , 2010, Fungal biology.
[13] T. C. White,et al. cis-Acting Elements within the Candida albicans ERG11 Promoter Mediate the Azole Response through Transcription Factor Upc2p , 2007, Eukaryotic Cell.
[14] D. Perlin. Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[15] J. Berman,et al. Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans , 2006, Science.
[16] D. Sanglard,et al. TAC1, Transcriptional Activator of CDR Genes, Is a New Transcription Factor Involved in the Regulation of Candida albicans ABC Transporters CDR1 and CDR2 , 2004, Eukaryotic Cell.
[17] T. C. White,et al. Role of Candida albicans Transcription Factor Upc2p in Drug Resistance and Sterol Metabolism , 2004, Eukaryotic Cell.
[18] M. Bard,et al. Ergosterol gene expression in wild-type and ergosterol-deficient mutants of Candida albicans. , 2004, Medical mycology.
[19] D. Loebenberg,et al. Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to Azoles , 2004, Antimicrobial Agents and Chemotherapy.
[20] T. C. White,et al. The Candida albicans Lanosterol 14-α-Demethylase (ERG11) Gene Promoter Is Maximally Induced after Prolonged Growth with Antifungal Drugs , 2004, Antimicrobial Agents and Chemotherapy.
[21] Mi-Kyung Lee,et al. Drug resistance genes and trailing growth in Candida albicans isolates. , 2004, The Journal of antimicrobial chemotherapy.
[22] J. Heitman,et al. Disruption of Ergosterol Biosynthesis Confers Resistance to Amphotericin B in Candida lusitaniae , 2003, Antimicrobial Agents and Chemotherapy.
[23] D. Sanglard,et al. Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal Agents , 2003, Antimicrobial Agents and Chemotherapy.
[24] S. Morand,et al. Usefulness of Multilocus Sequence Typing for Characterization of Clinical Isolates of Candida albicans , 2002, Journal of Clinical Microbiology.
[25] D. Sanglard,et al. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.
[26] K. Nielsen,et al. Determination of ergosterol on mouldy building materials using isotope dilution and gas chromatography-tandem mass spectrometry. , 2000, Journal of chromatography. A.
[27] G. Bonn,et al. Histidine77, glutamic acid81, glutamic acid123, threonine126, asparagine194, and tryptophan197 of the human emopamil binding protein are required for in vivo sterol delta 8-delta 7 isomerization. , 1999, Biochemistry.
[28] R. Cannon,et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance , 1996, Antimicrobial agents and chemotherapy.